Sexual Health

Anogenital Warts

Anogenital warts are usually benign HPV-related epithelial lesions, most often associated with low-risk types 6 and 11; diagnose them clinically, biopsy atypical or treatment-resistant lesions, and choose observation, topical treatment or ablation by site, morphology, pregnancy status and patient preference.

In a nutshell

Anogenital warts are usually benign HPV-related lesions, most often associated with types 6 and 11, and are diagnosed clinically. Biopsy atypical, uncertain or treatment-resistant lesions. Observation is acceptable; otherwise choose imiquimod or podophyllotoxin for suitable external warts and cryotherapy or other ablation for keratinised, extensive, internal or resistant disease. Pregnancy changes treatment choice, and HPV vaccination is preventive rather than therapeutic.

Classic presentation

A sexually active adult has painless flesh-coloured papilliform or keratotic lesions on the genital or perianal skin, with no systemic illness and a typical appearance on careful examination.

Key points

  • Around 90% of anogenital warts are associated with low-risk HPV types 6 and 11; typical warts are benign but atypical lesions may contain dysplasia or malignancy.
  • Diagnosis is clinical after examining the whole external anogenital area and urethral meatus; biopsy bleeding, ulcerated, indurated, fixed, uncertain or non-responding lesions.
  • Observation is acceptable for small or asymptomatic lesions; there is no single best treatment and recurrence is common.
  • Imiquimod or podophyllotoxin suit selected external warts; cryotherapy or specialist ablation suits keratinised, extensive, internal or resistant disease.
  • Avoid self-applied topical agents in pregnancy or breastfeeding; use appropriate ablative options if treatment is necessary and do not perform caesarean birth solely to prevent HPV transmission.
  • HPV vaccination prevents new vaccine-type infection but does not treat established warts; eligible people should still follow routine cervical screening.

First-line investigation

Clinical inspection of the entire external anogenital area and urethral meatus, with internal examination, biopsy and sexual-health tests selected by symptoms, appearance and risk.

Management

Confirm typical disease and identify red flags

  • Examine the whole external area and meatus; biopsy atypical or uncertain lesions and refer internal, cervical, anal or potentially malignant disease appropriately.1

Explain and offer observation or treatment

  • Explain spontaneous regression, recurrence and treatment limits; observation is acceptable, while selected external warts may be treated with imiquimod or podophyllotoxin.1,5

Ablate resistant or site-inappropriate disease

  • Use cryotherapy, trichloroacetic acid, electrosurgery, excision or laser when lesions are keratinised, extensive, internal or resistant, with specialist site-specific care.1

Modify pregnancy, immunosuppression and safeguarding pathways

  • Avoid self-applied topical agents in pregnancy or breastfeeding, use safe ablative options when needed, biopsy atypical disease in immunosuppression and follow NICE safeguarding guidance for children and young people.1,4,5

Prevent, reassure and review selectively

  • Offer eligible HPV vaccination, continue cervical screening, explain condom limitations and lack of routine partner notification, and review persistent or incompletely responding lesions.1,2,3

Exam traps

  • Typical warts are benign, but bleeding, ulceration, induration, fixation, rapid growth, uncertainty or treatment failure should prompt biopsy rather than repeated empirical treatment.
  • HPV 6 and 11 cause most typical warts, but oncogenic HPV can coexist; do not equate a wart with a premalignant lesion or ignore atypical features.
  • Pregnancy and breastfeeding change treatment: do not use self-applied topical agents routinely; use specialist-approved ablative options when treatment is necessary.
  • HPV vaccination prevents infection and future disease but is not a treatment for existing warts, and vaccinated people still attend cervical screening.
  • Routine partner notification is not required, and the long variable latency means warts cannot date or prove a specific sexual contact.
  • Anogenital warts in a child or young person require safeguarding-sensitive assessment without assuming a single transmission route.

Illustrations

Small anogenital condylomaClinical photograph of a small raised papilliform condyloma on scrotal skin, illustrating a subtle presentation of anogenital warts.Bikepunk2, Wikimedia Commons · CC0

Key sources

  1. BASHH, National guideline for the management of anogenital warts in adults (Current UK sexual-health guideline covering examination, biopsy, treatment options, pregnancy, immunocompromise, vaccination and follow-up; published 2024 and page last updated 28 August 2024)Published 1 Feb 2024
  2. UKHSA/NHS England, HPV vaccination guidance for healthcare practitioners (Current UK practitioner guidance for HPV vaccine eligibility, schedules, immunosuppression, prevention of genital warts and ongoing cervical-screening advice; updated June 2023)Published 20 Jun 2023
  3. NHS Cervical Screening Programme, programme overview (Current UK screening information confirming that HPV vaccination does not replace routine cervical screening)
  4. NICE CG89, Child maltreatment: when to suspect maltreatment in under 18s (Current safeguarding guidance: consider sexual abuse in children or young people with anogenital warts while considering vertical and non-sexual transmission; last updated December 2025)Published 22 Jul 2009
  5. BNF, podophyllotoxin and imiquimod (Current UK prescribing reference for topical anogenital-wart treatments, contraindications, interactions and product-specific cautions)

This page is exam revision material, not medical advice, and must not be used for patient care. Always check drug doses against the BNF and current guidance. Full disclaimer.